BUY CIPLA INDIA. Steady growth, margin visibility amid headwinds. Target Price: Rs 675. Key drivers
|
|
- Randell Rich
- 6 years ago
- Views:
Transcription
1 13 NOV 2017 Quarterly Update BUY Target Price: Rs 675 Steady growth, margin visibility amid headwinds Cipla s Q2 EBITDA margin improved 156 bps YoY at 19.7% (despite 270 bps YoY decline in gross margin) led by operating leverage (higher domestic sales) and increasing cost efficiencies (which it expects to improve further in H2FY18/FY19). Management expectation of recovery in gross margin (to ~63.5%-64%) and steady India growth (at 14-15% YoY) are positive margin drivers, though it will be partly offset by higher competition in recently-launched grenvela and 200 bps increase in R&D to 8% of sales in H2. It expects filing/ approval intensity to ramp up with a good mix of differentiated products. Maintain BUY with revised TP of Rs 675 (21x Sep 19 EPS vs. 21x FY19E earlier) on strong domestic franchise coupled with scale-up in US with higher focus on R&D and relatively better regulatory track record. CMP : Rs 608 Potential Upside : 11% MARKET DATA No. of Shares : 805 mn Free Float : 63% Market Cap : Rs 490 bn 52-week High / Low : Rs 663 / Rs 479 Avg. Daily vol. (6mth) : 1.4 mn shares Bloomberg Code : Cipla IB Equity Promoters Holding : 37% FII / DII : 22% / 15% In-line revenue led by 12% YoY growth in India sales partially led by trade channel restocking. Normalized India sales (adjusted for excise duty impact under GST) grew 19% YoY. Trade channel inventory is ~8-10 days below pre-gst inventory level. Expects mid teen growth over remaining H2FY18 in India business. US business declined 3% YoY/ 4% QoQ to USD 96 mn owing to pricing pressure. Expects key product approvals in the US to drive good mix of differentiated product launches in the upcoming quarters. South Africa business grew 17% YoY in USD terms and 13% YoY in INR terms driven by above market growth in the private market. Europe business grew 14% YoY. API revenue grew 85% YoY (up 64% QoQ) driven by higher ARV sales to US/EU customers Strong EBITDA margin performance: Gross margin at 61.1% contracted 270 bps YoY/ 466 bps QoQ impacted by GST, certain inventory charges, and manufacturing of batch quantities of future R&D filings. It is expected to normalize to %. However, EBITDA margin improved 156 bps YoY /136 bps QoQ at 19.7% led by operational efficiencies, lower R&D spend. Other expenses at Rs 10.6 bn (flat YoY) stood at 26.7% of sales (29% of sales in Q2FY17). Staff cost at Rs 6.6 bn (declined 2% YoY) stood at 16.6% of sales (18.4% of sales in Q2FY17). Financial summary (Consolidated) Sales (Rs mn) 1,42,809 1,50,557 1,76,416 2,04,613 Adj PAT (Rs mn) 10,064 15,873 22,950 28,777 Con. EPS* (Rs.) EPS (Rs.) Key drivers (Continued on page 2 ) Growth (% ) FY17 FY18E FY19E US India EBITDA margin core-eps (1) Chg YOY (%) (26.1) P/E (x) RoE (%) RoCE (%) EV/E (x) DPS Source: *Consensus broker estimates, Company, Axis Capital ^cc: Constant Currency Price performance 140 Sensex Cipla Oct-16 Jan-17 Apr-17 Jul-17 Oct-17 01
2 ( Continued from page 1) Other concall highlights: (1) Margin guidance: Targets to improve EBITDA by 100 bps annually led by cost-saving initiatives; (2) ANDA filings: Filed 5 products in Q2, of which 2 are expected to be limited competition. On track to file ANDAs in FY18 (filed 8 in H1FY18); (3) R&D: R&D spends of Rs 2.5 bn (down 15% YoY) at 6.1% of Q2FY18 sales (vs. 8% in Q2FY17/6% in Q1FY18). Cipla expects R&D to scale up to ~8% of sales in H2FY18, with commencement of clinical trials for respiratory pipeline; (4) Capex: Rs 8 bn-8.5 bn in FY18 (Rs 1.69 bn in Q2FY18); (5) FCF of Rs 3.09 bn in Q2FY18; (6) Sevelamer: Significant price erosion seen given 4 generic players and authorized generic; (7) gseroflo (Advair) launch in Australia received well and has witnessed strong uptake; uptake in UK remains gradual EBITDA margin expansion driven by operational efficiency and control on spends (Rs mn) Q2'17 Q1'18 Q2'18 YoY (%) QoQ (%) Net sales 36,719 34,323 39, Other operating income Total revenue 37,510 35,251 40, Gross profit 24,210 23,484 25, Gross margin bps -466 bps Staff 6,753 6,729 6,608 (2) (2) % to Sales bps -304 bps Other Op. expenses 10,650 10,290 10,641 (0) 3 % to Sales bps -330 bps EBITDA 6,807 6,465 8, EBITDA margin bps 136 bps Interest Depreciation 2,292 2,134 3, Other Income 272 1,514 1, (25) PBT 4,436 5,565 5, Tax 719 1,308 1, Tax rate 16% 23% 24% 8 bps 0 bps Reported PAT 3,543 4,088 4, Source: Company *Q2FY18 depreciation contains USD 11 mn expenses related to impairment of Invagen assets, Q2FY18 other income contains ~USD 11 mn compensation under negotiated settlement amount Recovery in domestic business; good growth in South Africa (Rs mn) Q2'17 Q1'18 Q2'18 YoY (%) QoQ (%) India 14,690 12,710 16, South Africa 4,590 4,880 5, North America 6,640 6,460 6,180 (7) (4) North America (USD mn) (3) (4) Emerging Markets 8,300 7,250 8, Europe 1,330 1,640 1, (8) API 1,150 1,300 2, Others 810 1, (1) (21) Total 37,510 35,250 40, Source: Company, Axis 02
3 Pace of approvals improves for Cipla in CY17 YTD 13 NOV 2017 Quarterly Update Brand Sales No of Generic Approval Date Generic name Brand name Approval Facility (USD mn) Players Atorvastatin Calcium Tablet Lipitor FA Invagen Oxaliplatin Eloxatin FA Cipla US Lamvudine Tablets Epivir NA 8 FA Cipla US Darunavir Ethanolate Tablets Prezista TA Cipla US Abacavir, lamivusine Epzicom FA Cipla US Fenofibrate (Micronized) Capsules NA 38 8 FA Invagen Clindamycin Palmitate Hydrochloride (Oral Solution) Cleocin 71 6 FA Invagen Efavirenz Sustiva TA Cipla US Lisinopril and Hydrochlorothiazide Zestoretic FA Invagen Olopatadine Hcl - 0.2% Ophthalmic solution Pataday TA Cipla US Nevirapine - Oral Suspension Viramune NA 2 FA Cipla US Arformoterol Tartrate (Solution; Inhalation) Brovana TA Cipla US Bupropion Hcl Tablets Wellbutrin FA Invagen Sevelamer Carbonate Renvela FA Invagen Zoledronic Acid (4MG/Vial) Zometa 96 2 FA Cipla US Source: Company, USFDA Conference call highlights Guidance Filings: Targets ANDA filings in FY18. Filed 5 ANDA s in Q2FY18, of which its expects 2 filings to be limited competition Margin guidance: Targets to improve EBITDA by 100 bps annually led by its cost saving initiatives R&D: Expects R&D to increase to ~8% of sales in H2FY18 (~6.1% of sales in Q2FY18) with commencement of clinical trials for respiratory pipeline from Q3FY18 Capex: Rs 8 bn-8.5 bn in FY18 (Rs 1.69 bn in Q2FY18) North America (USD 96 mn, -3%YoY, 15% of Q2 sales) Key product approvals in the US to drive good mix of differentiated product launches in upcoming quarters grenvela: 4 generic players and an authorized generic player Cipla has cumulatively 71 ANDA s pending approval (incl. tentative approvals Cipla:49, Invagen: 22, Partnered ANDA s:11) including 12 FTF s (market size worth USD 20 bn). Targets ANDA filings in FY18 India (Rs 16.5 bn, +12% YoY, 40% of Q2 sales) Normalized India sales (adj. for excise duty impact under GST; Rs 1 bn impact) grew 19% YoY, partially led by channel restocking Channel inventory currently ~8-10 days below pre-gst inventory level Expects mid teen growth over remaining H2FY18 in India business South Africa (USD 81 mn, +17% YoY, 13% of Q2 sales) As per IMS MAT (Sep 17), Cipla grew at 11.3% in the private market vs. 9.5% market growth 03
4 Launched 8 new products in H1FY18 with a combined total market value of ZAR 490 mn in South Africa Emerging Markets (USD 71 mn, +15% YoY, 21% of Q2 sales) Double digit in-market sales growth across key DTM markets gseroflo (Advair) launch in Australia received well and, has witnessed strong uptake Business profitability improved during the quarter driven by greater share of high-margin SKUs in product mix Cipla s Global access business grew 7% YoY; increasingly focusing on partnering with other regional governments to increase access to affordable care in various parts of Africa Europe (USD 23 mn, +18% YoY, 4% of Q2 sales) Launched gseroflo in Ireland during the quarter; to launch soon in other parts of Europe including Sweden and Finland Improvement in overall profitability driven by focus on high margin SKUs and nimble operations API (USD 33 mn, +92% YoY, 5% of Q2 sales) Strong growth in Q2FY18 on higher ARV sales (API supplies to customer/partner for prospective monetization of ARV generic formulations Cipla may receive profit share from partners) P&L and balance sheet highlights Lower gross margin in Q2FY18 impacted by certain inventory charges, manufacturing of batch quantities of future R&D filings, NPPA-led pricing adjustments and product mix Expects gross margin to improve to 63.5%-64% in upcoming quarters Higher D&A in Q2FY18 due to write-down of US-based intangibles due to delay in launch of certain products (~USD 11mn) Higher other income in Q2FY18 on receipt of compensation under negotiated settlement amount (~USD 11 mn) FCF of Rs 3.09 bn in Q2FY18 Capex of Rs 1.69 bn in Q2FY18 Gross debt of USD 550 mn as of end H1FY18. Outstanding working capital loans of USD 187 mn Balance sheet hedges of USD 14 mn, ZAR 255 mn, EUR 6 mn, cash flow hedges of USD 108 mn, ZAR 252 mn 04
5 (%) Volumes declined in Q2 18 Volume Price New product (1) (1) (4) (10) FY15 FY16 FY17 Q2'17 Q1'18 Q2'18 Source: AIOCD led by weak anti-infective sales YoY growth % of sales FY16 FY17 Q2'17 Q1'18 Q2'18 Respiratory 31% 12% 12% 14% 8% 4% Anti-Infectives 25% 14% -2% 1% -3% -11% Cardiac 12% 7% 13% 5% 3% -4% Gastro Intestinal 8% 21% 12% 11% 4% -9% Opthal 3% 15% 6% -3% 2% -7% Neuro / CNS 4% 17% 9% -13% -1% -6% Pain / Analgesics 3% 31% 12% 10% -2% -7% Derma 3% 14% 9% 6% -9% -16% Gynaecological 2% 8% -1% -6% -9% -18% Vit/Min/ Nut 2% 7% -5% 7% -12% -9% Total (Rs bn) 53 13% 8% 6% 3% -1% Source: AIOCD We expect strong scale-up in US revenue Invagen + Exelan Base Cipla Base business New Launches (USD mn) FY16 FY17 FY18E FY19E FY20E Source: Company, Axis Capital 05
6 Financial summary (Consolidated) Profit & loss (Rs mn) Net sales 1,42,809 1,50,557 1,76,416 2,04,613 Other operating income 3,494 4,193 5,241 6,551 Total operating income 1,46,302 1,54,750 1,81,657 2,11,164 Cost of goods sold (53,171) (54,953) (63,510) (73,661) Gross profit 93,131 99,796 1,18,147 1,37,503 Gross margin (%) Total operating expenses (68,373) (70,451) (79,567) (91,254) EBITDA 24,758 29,345 38,580 46,249 EBITDA margin (%) Depreciation (13,229) (9,957) (10,892) (11,747) EBIT 11,529 19,388 27,688 34,502 Net interest (1,594) (1,183) (685) (125) Other income 2,287 3,173 2,773 2,773 Profit before tax 12,222 21,379 29,776 37,151 Total taxation (1,798) (5,131) (6,551) (8,173) Tax rate (%) Profit after tax 10,424 16,248 23,225 28,977 Minorities (360) (375) (275) (200) Profit/ Loss associate co(s) Adjusted net profit 10,064 15,873 22,950 28,777 Adj. PAT margin (%) Net non-recurring items (1,796) Reported net profit 8,268 15,873 22,950 28,777 Balance sheet (Rs mn) Paid-up capital 1,609 1,609 1,609 1,609 Reserves & surplus 1,23,645 1,37,582 1,58,596 1,85,437 Net worth 1,25,254 1,39,191 1,60,205 1,87,046 Borrowing 41,126 31,126 17,126 3,126 Other non-current liabilities 7,569 7,569 7,569 7,569 Total liabilities 1,78,331 1,82,643 1,89,932 2,02,973 Gross fixed assets 1,13,053 1,20,214 1,27,442 1,35,233 Less: Depreciation (18,333) (28,290) (39,182) (50,929) Net fixed assets 94,720 91,924 88,259 84,304 Add: Capital WIP 16,830 16,830 16,830 16,830 Total fixed assets 1,11,550 1,08,754 1,05,089 1,01,134 Total Investment 9,748 9,942 10,141 10,344 Inventory 34,853 41,229 47,039 54,218 Debtors 24,974 26,812 31,417 36,438 Cash & bank 6,242 7,249 8,278 14,238 Loans & advances 22,334 20,624 24,167 28,029 Current liabilities 31,369 31,967 36,198 41,428 Net current assets 57,034 63,947 74,702 91,495 Other non-current assets Total assets 1,78,331 1,82,643 1,89,932 2,02,973 Source: Company, Axis Capital Cash flow (Rs mn) 13 NOV 2017 Quarterly Update Profit before tax 12,222 21,379 29,776 37,151 Depreciation & Amortisation 13,229 9,957 10,892 11,747 Chg in working capital 2,307 (5,906) (9,725) (10,834) Cash flow from operations 24,849 21,481 25,077 30,015 Capital expenditure (12,862) (8,500) (8,500) (9,000) Cash flow from investing (13,127) (8,500) (8,500) (9,000) Equity raised/ (repaid) Debt raised/ (repaid) (8,482) (10,000) (14,000) (14,000) Dividend paid (1,936) (1,936) (1,936) (1,936) Cash flow from financing (10,417) (11,936) (15,936) (15,936) Net chg in cash 1,306 1, ,079 Key ratios OPERATIONAL FDEPS (Rs) CEPS (Rs) DPS (Rs) Dividend payout ratio (%) GROWTH Net sales (%) EBITDA (%) (0.2) Adj net profit (%) (26.0) FDEPS (%) (26.1) PERFORMANCE RoE (%) RoCE (%) EFFICIENCY Asset turnover (x) Sales/ total assets (x) Working capital/ sales (x) Receivable days Inventory days Payable days FINANCIAL STABILITY Total debt/ equity (x) Net debt/ equity (x) (0.1) Current ratio (x) Interest cover (x) VALUATION PE (x) EV/ EBITDA (x) EV/ Net sales (x) PB (x) Dividend yield (%) Free cash flow yield (%) Source: Company, Axis Capital 06
7 Disclosures: The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). 1. Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India s largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on 2. ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity. 3. ASL has no material adverse disciplinary history as on the date of publication of this report. 4. I/We, authors (Research team) and the name/s subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associates do not have any material conflict of interest. I/we have not served as director, officer or employee in the subject company. Research Team Sr. No Name Designation 1 Hiren Trivedi Research Associate hiren.trivedi@axissecurities.in 2 Kiran Gawle Associate kiran.gawle@axissecurities.in 5. ASL or its associates has not received any compensation from the subject company in the past twelve months. ASL or its Research Analysts has not been engaged in market making activity for the subject company. 6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have: i. Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or; ii. Managed or co-managed public offering of the securities from the subject company of this research report and / or; iii. Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report; ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report Term& Conditions: This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report. 07
8 DEFINITION OF RATINGS Disclaimer: Ratings Expected absolute returns over months BUY More than 10% HOLD Between 10% and -10% SELL Less than -10% Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient s specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advise necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document. ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein. Copyright in this document vests with Axis Securities Limited. Axis Securities Limited, Corporate office: Unit No. 2, Phoenix Market City, 15, LBS Road, Near Kamani Junction, Kurla (west), Mumbai , Tel No / , Regd. off.- Axis House, 8th Floor, Wadia International Centre, PandurangBudhkarMarg, Worli, Mumbai Compliance Officer: AnandShaha, compliance.officer@axisdirect.in, Tel No: SEBI-Portfolio Manager Reg. No. INP
BUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights
JK 20 NOV 2017 Quarterly Update BUY Target Price: Rs 1,220 White cement steals the show JK Cement s (JKCE) Q2FY18 EBITDA at Rs 2.1 bn (up 30% YoY) was higher than our and consensus estimates, mainly due
More informationBUY. At inflection point NTPC. Target Price: Rs 197. Key highlights. Financial summary (Standalone) Y/E March FY16 FY17 FY18E FY19E.
At inflection point Q2FY18 adjusted PAT grew 12% YoY at Rs 27 bn (vs. our estimate Rs 26 bn) in tandem with 17% YoY rise in regulated equity. Core RoE is still healthy at 20.2% though it contracted ~174
More informationHOLD. Margins to improve from Q2 AMBUJA CEMENTS. Target Price: Rs 232. Other highlights
AMBUJA S 4 MAY 2017 Quarterly Update HOLD Target Price: Rs 232 Margins to improve from Q2 Q1CY17standalone EBITDA at Rs 4.0 bn was in line withconsensus estimate.volume was up 3% YoY to 6 mnt. Realization
More informationHe is BTech from IIT Bombay ( , Aeronautical Engineering) and MS from Cornell University ( , Mechanical Engineering).
Stabilizing the Ship; focus shifts to strategy Infosys has appointed Mr. Salil S Parekh as CEO and MD effective January 2, 2018 for a period of 5 years. He would be based out of Bengaluru (India). Also,
More informationBUY MULTI COMMODITY EXCHANGE OF INDIA. Strong Q2; All eyes on option volumes. Target Price: Rs 1,280. Concall highlights
25 OCT 2017 Quarterly Update BUY Target Price: Rs 1,280 Strong Q2; All eyes on option volumes Revenue increased ~5% QoQ to Rs 915 mn due to higher traded value (up ~17% QoQ) led by bullion (up ~17% QoQ)
More informationBUY. Robust quarter with clear growth visibility DILIP BUILDCON. Target Price: Rs 610. Financial summary (Standalone) Y/E March FY16 FY17 FY18E FY19E
Robust quarter with clear growth visibility Dilip Buildcon s (DBL) Q1FY18 sales grew 60% YoY to Rs 16.6 bn, ahead of our estimate of Rs 12.0 bn and consensus of Rs 13.6 bn. EBITDA was up 47% at Rs 3.0
More informationBUY MULTI COMMODITY EXCHANGE OF INDIA. Demonetization,GST uncertainty impact Q4. Target Price: Rs 1,397. Concall highlights
09 MAY 2017 Quarterly Update BUY Target Price: Rs 1,397 Demonetization,GST uncertainty impact Q4 Revenue declined 12% QoQ at Rs 874 mn due to lower traded value (down 10% QoQ). Bullion (~35% of traded
More informationBUY. Outperformance continues GULF OIL LUBRICANTS INDIA. Target Price: Rs 1,000. Hike estimates and TP; maintain BUY
Outperformance continues Gulf Oil s core volumes grew 7% YoY in Q1FY18 (vs. 10% normal growth) even as GST-led destocking led to 10-15% volume degrowth for peer lubricant players. Volumes are likely to
More informationHold Target Price: Rs 574
03 MAY 2017 Quarterly Update Hold Target Price: Rs 574 Q4FY17: Macro overhang persists SQS India BFSI Ltd delivered a modest performance in Q4FY17, with earnings (PAT) coming in at Rs 4.4 Cr, down 58.8%
More informationHOLD. Performance remains weak COLGATE-PALMOLIVE INDIA. Target Price: Rs 900
HOLD Target Price: Rs 900 Performance remains weak Net sales grew only 3% YoY as volumes declined ~3% due to sustained pressure in wholesale. Toothpaste market share declined 120 bps YoY to 54.1% but toothbrush
More informationBUY. GST pressures dealt well HINDUSTAN UNILEVER. Target Price: Rs 1,400. Key drivers (%) FY16 FY17 FY18E FY19E
GST pressures dealt well Q2 tops estimates: Net sales, EBITDA and adj. PAT grew 7%, 20% and 19%, vs. consensus expectation of 7%, 14% and 11%. Like to like^ (LTL) domestic consumer revenue grew ~10% on
More informationHOLD. Buyback of Old Mutual s stake in K-Life KOTAK MAHINDRA BANK. Target Price: Rs 965
4 MAY 17 Flash Note HOLD Target Price: Rs 965 Buyback of Old Mutual s stake in K-Life Event: Kotak Mahindra Bank (KMB) released a statement today announcing plans to buy back Old Mutual s (foreign partner)
More informationChange EPS. (Rs) FY
17 AUG 217 / Quarterly Update BUY Target Price: Rs. 662 : Revenue up 21% Y-o-Y, strong growth in Non-GLE segment GMM Pfaudler Ltd(GMM) in 1QFY18posted revenues of Rs 69 Cr. (up 21% Y-o-Y, down 13% Q-o-Q)
More informationBUY. Strong quarter, bright outlook MAHINDRA CIE AUTOMOTIVE. Target Price: Rs 274. Takeaways from concall. Key drivers (%)
MAHINDRA CIE MOTIVE Strong quarter, bright outlook Q4CY17 results were 6% ahead of estimates at operational level, as both India and Europe operations continued to deliver on both topline and EBITDA margin
More informationHOLD PVR. Operating matrix healthy; footfalls subdued. Target Price: Rs 1,520. Key highlights
Operating matrix healthy; footfalls subdued Q3 was largely in line with expectations. Limited box-office success led to lower footfalls (down 2%) and occupancy (~29% vs. 32% YoY) despite ~7% increase in
More informationInvestment Horizon: Though the ideal investment horizon for such ideas remain 6-9 months, our picks may provide some profit-making
Pick of the Week 1 Pick of the Week In an ever-changing business environment, some of our investment ideas seem more convincing than others due to better earning visibility and/or attractive valuation.
More informationHOLD. Going aggressive in hair oils DABUR INDIA. Target Price: Rs 325. Key drivers (%) FY17 FY18E FY19E
25 OCT 2017 Company Update HOLD Target Price: Rs 325 Going aggressive in hair oils Dabur India has stepped up its aggression in the Indian hair oils segment. Recent advertisements show Dabur offering its
More informationInvestment Horizon: Though the ideal investment horizon for such ideas remain 6-9 months, our picks may provide some profit-making
Pick of the Week 1 Pick of the Week In an ever-changing business environment, some of our investment ideas seem more convincing than others due to better earning visibility and/or attractive valuation.
More informationBUY. Structural changes in the making CAPITAL FIRST. Target Price: Rs 920. Key drivers
9 OCT 217 Company Update BUY Target Price: Rs 92 Structural changes in the making We recently interacted with the management of Capital First (CAFL) to get insights of the business and the way forward.
More informationBUY Target Price: Rs 1,218
New growth avenues Interaction with Bharat Forge (BFL) top management and tour of its technical centre suggests strong growth opportunities in new areas like defense, aerospace, and auto transmission.
More informationBUY STEEL STRIPS WHEELS LTD. Target Price: Rs Q4FY17: Heavier wheels outperform, strong growth triggers ahead FINANCIAL SUMMARY
12 JUNE 2017 Quarterly Update BUY Target Price: Rs 1061 Q4FY17: Heavier wheels outperform, strong growth triggers ahead Steel Strips Wheels Limited s (SSWL) in 4QFY17 posted revenues of Rs 380 Cr. (up
More informationHOLD. FY18 off to a good start GODREJ PROPERTIES. Target Price: Rs 486. Q4FY17 key highlights
09 MAY 2017 Quarterly Update HOLD Target Price: Rs 486 FY18 off to a good start Godrej Properties Ltd (GPL) has booked pre-sales of Rs 9-10 bn in April 2017driven by launch of 3 projects The Trees Origins
More informationBUY. Quess likely to be spun-off; stay invested THOMAS COOK (INDIA) Target Price: Rs 320
Quess likely to be spun-off; stay invested Thomas Cook s (TCIL) board has approved the proposal of a corporate restructuring exercise that would enable the company to focus on Travelrelated businesses
More informationHOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance
RAMCO S HOLD Target Price: Rs 503 Deleveraging story playing out Ramco Cements total debt reduced by a massive Rs 5 bn to Rs 22 bn in FY16. The company generated total EBITDA of Rs 11.5 bn in FY16 and
More informationBUY. FY17 a blip; gradual recovery ahead APOLLO HOSPITALS ENTERPRISE. Target Price: Rs 1,472
FY17 a blip; gradual recovery ahead Apollo Hospital s FY17 earnings miss (EBITDA at Rs 7.3 bn vs. our expectation of Rs 7.8 bn) was largely due to lower than expected margin in matured hospitals. Stent
More informationBUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E
RAMCO S BUY Target Price: Rs 435 Efforts on cost cutting paying off Q2 EBITDA at Rs 2.8 bn (up 30% YoY) was ahead of our estimates due to lower-than-expected costs. Average costs (excluding freight) declined
More informationNOW ON APP Research at your finger tips
NOW ON APP Research at your finger tips 15 FEB 2018 Quarterly Update BUY Target Price: Rs 470 ODC project takes breather; to rebound in Q4 Q3 pre-sales declined QoQ to Rs 1 bn (Rs 1.7 bn in Q2) on lower
More informationBUY. Weak P&L performance, good b/s show POWER FINANCE CORP. Target Price: Rs 135. Financial summary (Standalone) Y/E March FY17 FY18E FY19E FY20E
Weak P&L performance, good b/s show PFC reported a disappointing P&L performance with Q3 PAT at Rs 16 bn (down 17.7% YoY; our est. Rs 18.6 bn), primarily led by sharp decline in NIM (down 35 bps QoQ at
More informationBUY. IIB-BHAFIN merger a done deal INDUSIND BANK. Target Price: Rs 1,920. Financial summary (Standalone) Y/E March FY16 FY17 FY18E FY19E
IIB-BHAFIN merger a done deal The long awaited IIB-BHAFIN merger is finally sailing through with the bank acquiring the MFI in a share swap ratio of ~0.64x, entailing 639 shares of IIB for 1,000 shares
More informationBUY. Multiple margin tailwinds; BUY HINDUSTAN UNILEVER. Target Price: Rs 1,010. Key drivers (%) FY16 FY17E FY18E FY19E
Multiple margin tailwinds; BUY After maintaining a neutral call on HUVR for past two years, we upgrade it to BUY on the back of (i) multiple margin tailwinds, (ii) slow but steady improvement in volume
More informationBUY. Shedding non-core assets TATA POWER. Target Price: Rs 136. Financial summary (Consolidated) Key drivers. Price performance
Shedding non-core assets Q3 PAT at Rs 6.3 bn beat our estimate of Rs 5.7 bn mainly due to lower-than-expected losses at Mundra UMPP on improving operational metrics. Up-to-mark performance by coal companies
More informationBUY. Well poised for strong growth RBL BANK. Target Price: Rs 650. Key highlights. Financial summary (Standalone) Y/E March FY17 FY18E FY19E FY20E
4 APR 218 Visit Note BUY Target Price: Rs 65 Well poised for strong growth We met with the senior management of RBL and came back confident on its outlook and execution capabilities. Growth rates to remain
More informationBUY. Q4 hurt by MFI business EQUITAS HOLDINGS. Target Price: Rs 190
Q4 hurt by MFI business Q4FY17 was subdued due to moderation in AUM growth, significant decline in margin and further deterioration in headline asset quality. Additionally, higher operating expenses (due
More informationFY16 FY17 FY18E FY19E
24 JUL 2017 Annual Report Analysis BUY Target Price: Rs 6,025 Annual Report Analysis GSK Consumer s FY17 annual report largely highlights the company s renewed thrust on the core portfolio by making the
More informationBUY. Recovery ahead; upgrade to BUY BAJAJ AUTO. Target Price: Rs 3,905. Key takeaways from our meeting with the management
BAJAJ 22 JAN 2018 Company Update BUY Target Price: Rs 3,905 Recovery ahead; upgrade to BUY Bajaj Auto had a tough last 5-6 years due to weakness in exports and domestic 2Ws. Consequently, even after 7%
More informationSymphony Ltd. RESULT UPDATE 31st October 2017
. RESULT UPDATE 31st October 2017 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update Q2FY18 II 31st October 2017. CMP INR 1,465 Target INR 1,700 Potential
More informationCummins India Ltd Bloomberg Code: KKC IN
Company Update Margins Under Pressure; Domestic Recovery Underway Half-yearly revenue was flat; margins were under pressure: Cummins India revenue, EBITDA and PAT for H1FY17 reached to Rs.24,784mn, Rs.4,649mn
More informationITC Ltd. RESULT UPDATE 27th October, 2017
. RESULT UPDATE 27th October, 2017 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update - II 27th October, 2017 CMP INR 269 Target INR 349 Potential Upside
More informationAhluwalia Contracts (India)
May-14 Jul-14 Aug-14 Sep-14 Oct-14 Dec-14 Jan-15 Feb-15 Apr-15 May-15 India Research Infrastructure May 22, 215 QUARTERLY REVIEW Bloomberg: AHLU IN Reuters: AHLU.BO BUY Better performance ahead ACIL posted
More informationNear-term pressure, but long-term outlook positive
INDUSTRY IT CMP (as on 2 Nov 2015) Rs 1,812 Target Price Rs 2,050 Nifty 8,051 Sensex 26,559 KEY STOCK DATA Bloomberg ECLX IN No. of Shares (mn) 30 MCap (Rs bn) / ($ mn) 55/843 6m avg traded value (Rs mn)
More informationFineotex Chemical Ltd
Company Update Decent Performance under Macroeconomic Pressure; Business Traction to Continue: Fineotex Chemical recorded decent set of result as consolidated sales grew by 1.1% YoY (largely in line) to
More informationSQS India BFSI Ltd HOLD. Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E
Company Update Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E EBITDA Margins recovered by 618 bps QoQ: The company has witnessed many challenges over the year FY17 starting
More informationMarico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015
RESULTS REVIEW 4QFY15 29 APR 2015 Marico Kaya INDUSTRY FMCG CMP (as on 28 Apr 2015) Rs 1,635 Target Price Rs 1,823 Nifty 8,240 Sensex 27,226 KEY STOCK DATA Bloomberg MAKA IN No. of Shares (mn) 13 MCap
More informationVisaka Industries Ltd
Company Update Superior Product Mix & New Age Markets to Aid Growth New investments to aid growth: Visaka continues to give a good set of numbers. YoY EPS grew at 142% aided by a revenue growth of 1.5%
More informationNestle India Ltd. RESULT UPDATE
RESULT UPDATE 15th May 2017 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 India Equity Institutional Research II Result Update Q1CY17 II 15th May, 2017 CMP INR 6819 Target INR 7075 Potential Upside
More informationConsolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE
Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 2904 Recommendation CMP Target Price BUY Rs. 312 Rs. 443 Better times ahead! reported a good set of numbers in
More informationHealty cigarette-driven growth
INDUSTRY FMCG CMP (as on 27 Jul 2017) Rs 289 Target Price Rs 353 Nifty 10,021 Sensex 32,383 KEY STOCK DATA Bloomberg ITC IN No. of Shares (mn) 12,161 12,162 MCap (Rs bn)/(us$ mn) 3,509/54,743 6m avg traded
More informationHOLD. Cipla Ltd Pharmaceuticals RETAIL EQUITY RESEARCH
Q3FY18 RESULT UPDATE RETAIL EQUITY RESEARCH Cipla Ltd Pharmaceuticals BSE CODE: 500087 NSE CODE: CIPLA Bloomberg CODE: CIPLA:IN SENSEX: 33,704 HOLD Rating as per Large cap 12months investment period CMP
More informationHCC BUY. Infrastructure April 10, QIP step in the right direction EVENT UPDATE. India Research. Bloomberg: HCC IN Reuters: HCNS.
Jan-14 Mar-14 Apr-14 May-14 Jul-14 Aug-14 Sep-14 Nov-14 Dec-14 Jan-15 India Research Infrastructure April 10, 2015 EVENT UPDATE Bloomberg: IN Reuters: HCNS.BO BUY QIP step in the right direction has successfully
More informationMahindra & Mahindra. Source: Company Data; PL Research
Tractors drive Q2 performance; Accumulate November 11, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating Accumulate Price Rs1,242 Target Price Rs1,503 Implied Upside 21.0% Sensex 26,819 Nifty
More informationSimplex Infrastructures
May-14 Jul-14 Aug-14 Sep-14 Nov-14 Dec-14 Jan-15 Mar-15 Apr-15 May-15 India Research Infrastructure May 27, 2015 QUARTERLY REVIEW Bloomberg: SINF IN Reuters: SINF.BO HOLD Working capital ease to improve
More informationKey estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20,
: price: EPS: How does our one year outlook change? We maintain rating on Aurobindo post the company s 3QFY16 results. Revenue growth for the quarter was 10% yoy: US sales of $238mn (vs. estimate of $251mn
More informationCrompton Greaves Consumer Electricals
INDUSTRY APPLIANCES CMP (as on 27 Oct 2017) Rs 219 Target Price Rs 268 Nifty 10,323 Sensex 33,157 KEY STOCK DATA Bloomberg CROMPTON IN No. of Shares (mn) 627 MCap (Rs bn)/(us$ mn) 137/2,106 6m avg traded
More informationTVS Motors. Source: Company Data; PL Research
Margins trajectory looking up ; Accumulate November 01, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs709
More informationGillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance
2QFY19 Result Update Gillette India 13 February 2019 Reuters: GILE.NS; Bloomberg: GILL IN Marketing Investments Mask Improved Top-line Performance Gillette India s (GILL) 2QFY19 operating and net earnings
More informationMphasis. Increased confidence on margins. Source: Company Data; PL Research
Increased confidence on margins July 25, 2016 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Rating BUY Price Rs540 Target Price Rs570 Implied Upside 5.6% Sensex 28,095 Nifty 8,636 (Prices as
More informationCMP* (Rs) 1,033 Upside/ (Downside) (%) (0.3) Bloomberg Ticker Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452
2QFY18 Result Update October 31, 2017 Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452 US Biz to Remain Weak; Maintain Led by weak performance in the US markets, (LPC) has delivered a weak
More informationMaruti Suzuki. Source: Company Data; PL Research
Healthy operating performance; Accumulate October 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating Accumulate Price Rs5,860 Target Price Rs6,356 Implied Upside 8.5% Sensex 27,916 Nifty
More informationHindustan Unilever Ltd.
. RESULT UPDATE 18 th July 2017 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 Jul-17 125 105 India Equity Institutional Research II Result Update - FY18 II 18th July, 2017 CMP INR 1158 Target INR 1206 MARKET
More informationHindustan Unilever (RHS)
Jul-14 Aug-14 Oct-14 Nov-14 Dec-14 Feb-15 Mar-15 Apr-15 Jun-15 Jul-15 India Research FMCG July 22, 2015 QUARTERLY REVIEW Bloomberg: HUVR IN Reuters: HLL.BO SELL Higher A&P drove volume growth HUL s Q1FY16
More informationBHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188
RESULTS REVIEW 1QFY15 13 AUG 2014 BHEL SELL INDUSTRY CAPITAL GOODS CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188 Nifty 7,727 Sensex 25,881 KEY STOCK DATA Bloomberg/Reuters BHEL IN/BHEL.BO No. of Shares
More informationTata Consultancy Services
Tata Consultancy Services SALES NOTE 19 th May 2017 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 India Equity Institutional Research II Sales Note II 19th May, 2017 CMP INR 2536 Target INR 2833 Potential
More informationMaruti Suzuki. Source: Company Data; PL Research
Run continues, Royalty reduction positive ; Buy January 29, 2018 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating BUY Price Rs9,277
More informationInitiating Coverage. Uflex Ltd.
2904 Recommendation CMP Target Price BUY Rs. 283 Rs. 444 Better times ahead! reported a good set of numbers for the year FY18 and for Q4. Sales for the quarter increase by 11.8% YoY to Rs 1809.8 Cr and
More informationJubilant FoodWorks NEUTRAL RESULTS REVIEW 4QFY17 30 MAY Highlights of the quarter
INDUSTRY FMCG CMP (as on 29 May 17) Rs 94 Target Price Rs 995 Nifty 9,65 Sensex 31,19 KEY STOCK DATA Bloomberg JUBI IN No. of Shares (mn) 66 MCap (Rs bn)/(us$ mn) 62/962 6m avg traded value (Rs mn) 574
More informationD-Link India (DLILIM) 105
Company Update Rating matrix Rating : Buy Target : 140 Target Period : 18-24 months Potential Upside : 34% What s Changed? Target Changed from 150 to 140 EPS FY18E Changed from 11.4 to 9.5 EPS FY19E Introduced
More informationInfibeam Incorporation Ltd.
RESULT UPDATE 16 th August, 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-2017-vote-now
More informationCrompton Greaves Consumer Electricals
INDUSTRY APPLIANCES CMP (as on 27 July 2017) Rs 209 Target Price Rs 252 Nifty 10,021 Sensex 32,383 KEY STOCK DATA Bloomberg CROMPTON IN No. of Shares (mn) 627 MCap (Rs bn)/(us$ mn) 131/2,046 6m avg traded
More informationSuzlon Energy Ltd RESULT UPDATE 16th August, 2017
RESULT UPDATE 16 th August, 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-2017-vote-now
More informationAsian Paints. Source: Company Data; PL Research
Premium valuations to sustain, Accumulate October 4, 17 Amnish Aggarwal amnishaggarwal@plindia.com +91 Gaurav Jogani gauravjogani@plindia.com +91 8 Rating Accumulate Price Rs1,1 Target Price Rs1,9 Implied
More informationTV Today Network BUY. Performance Update CMP. `323 Target Price `498. 3QFY2019 Result Update Media. Investment Period 12 Months
Jan-16 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 Jul-17 Oct-17 Jan-18 Apr-18 Jul-18 Oct-18 Jan-19 3QFY2019 Result Update Media February 14, 2019 TV Today Network Performance Update Y/E March (` cr) 3QFY19 3QFY18
More informationAlkem Labs BUY RESULTS REVIEW 1QFY19 11 AUG story remains on-track. Maintain BUY with a revised TP of Rs 2,410 (24x FY20E EPS).
INDUSTRY PHARMA CMP (as on 10 Aug 2018) Rs 2,060 Target Price Rs 2,410 Nifty 11,430 Sensex 37,869 KEY STOCK DATA Bloomberg ALKEM IN No. of Shares (mn) 120 MCap (Rs bn) / ($ mn) 246/3,576 6m avg traded
More informationMaruti Suzuki India BUY. Performance Update. CMP `6,705 Target Price `8,552. 2QFY2019 Result Update Automobile. Historical share price chart
Oct-15 Jan-16 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 Jul-17 Oct-17 Jan-18 Apr-18 Jul-18 Oct-18 2QFY2019 Result Update Automobile November 3, 2018 Maruti Suzuki India Performance Update Y/E March (` cr) 2QFY19
More informationMusic Broadcast BUY. Performance Update. CMP Target Price `329 `475. 2QFY2019 Result Update Media. Historical share price chart.
Mar-17 May-17 Jul-17 Sep-17 Nov-17 Jan-18 Mar-18 May-18 Jul-18 Sep-18 2QFY2019 Result Update Media November 3, 2018 Music Broadcast Performance Update Y/E March (` cr) 2QFY19 2QFY18 % yoy 1QFY19 % qoq
More informationAmber Enterprises India Ltd
3QFY2019 Result Update Consumer Durable February 16, 2019 Amber Enterprises India Ltd Performance Update (` cr) 3QFY19 3QFY18 % yoy 2QFY19 % qoq Revenue 388.8 338.4 14.9 226.3 71.8 EBITDA 22.1 24.1 (8.2)
More informationCummins India. Source: Company Data; PL Research
Technology leadership, cost optimization key focus October 28, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs852
More informationPrabhat Dairy Ltd. RESULT UPDATE 8th June, 2018
RESULT UPDATE 8 th June, 2018 Sep-15 Jan-16 May-16 Sep-16 Jan-17 May-17 Sep-17 Jan-18 May-18 India Equity Institutional Research II Result Update - Q4FY18 II 8 th June, 2018 2 Under Expansion Mode CMP
More informationColgate-Palmolive India Ltd.
RESULT UPDATE 5th February, 2018 Feb-15 Aug-15 Feb-16 Aug-16 Feb-17 Aug-17 Feb-18 India Equity Institutional Research II Result Update - Q3FY18 II 5th February, 2018 CMP INR 1,120 MARKET DATA Target INR
More informationGarware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months
2QFY217 Result Update Textile November 16, 216 Garware Wall Ropes Performance Highlights Quarterly Data (`cr) 2QFY17 2QFY16 % yoy 1QFY17 % qoq Revenue 232 214 8.5 225 3.3 EBITDA 4 26 5.9 31 29.4 Margin
More informationDr Reddy s Laboratories
: price: EPS: How does our one year outlook change? We maintain rating on DRRD post the company s 3QFY16 results Revenue growth for the quarter was muted (3% yoy) due to disappointing performances in Russia
More informationCummins India. Growth/margin bottoming. Source: Company Data; PL Research
Growth/margin bottoming May 25, 2018 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs704 Target Price Rs928 Implied Upside 31.8%
More informationFinancials/Valuation. 1Mn 3Mn 1Yr P/B (X) Absolute (7.8) (6.3) (5.3) P/E (x) Rel.to Nifty (6.5) (8.6) (25.0) Recent Developments:
Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 08-Feb-18 Bloomberg- INDUSTRY - CIPLA IN BSE Code - 500087 NSE Code - NIFTY - PHARMACEUTICAL CIPLA 10476 Comapany
More informationBLS International Services
INDUSTRY IT Processing CMP (as on 23 May 218) Rs 17 TP Rs 23 Nifty 1,43 Sensex 34,345 KEY STOCK DATA Bloomberg BLSIN IN No. of Shares (mn) 12 MCap (Rs bn) / ($ mn) 18/255 6m avg traded value (Rs mn) 89
More informationJubilant FoodWorks BUY RESULTS REVIEW 1QFY18 18 JULY Highlights of the quarter
INDUSTRY FMCG CMP (as on 17 Jul 17) Rs 1,273 Target Price Rs 1,45 Nifty 9,916 Sensex 32,75 KEY STOCK DATA Bloomberg JUBI IN No. of Shares (mn) 66 MCap (Rs bn)/(us$ mn) 84/1,35 6m avg traded value (Rs mn)
More informationBritannia Industries Ltd.
. RESULT UPDATE 9th August, 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-2017-vote-now
More informationLupin Ltd. RESULT UPDATE 31 st October 2017
RESULT UPDATE 31 st October 217 22 nd May 217 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update Q2FY18 II 31st October, 217 Lupin Ltd CMP INR 127 Target
More informationThermax. Source: Company Data; PL Research
Near term outlook muted, working on building a strong base November 11, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price
More informationLarsen & Toubro Ltd.
Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Volume No.. III Issue No. 163. Larsen & Toubro Ltd. February 26, 2018 BSE Code: 500510 NSE Code: LT Reuters Code:
More informationCoal India. Source: Company Data; PL Research
Misses estimates; Higher costs dims hope for earnings recovery February 13, 2017 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Rating Reduce Price Rs325 Target Price Rs320 Implied Upside 1.5%
More informationAllcargo Logistics. Source: Company Data; PL Research
Slow capex continue to impact PES, weak show continues May 24, 2018 Keyur Pandya keyurpandya@plindia.com +912266322247 R Sreesankar rsreesankar@plindia.com +912266322214 Rating Accumulate Price Rs120 Target
More informationBritannia Industries Ltd.
. RESULT UPDATE 30th May, 2017 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 India Equity Institutional Research II Result Update - Q4FY17 II 30 th May, 2017 2 Growth Path ahead CMP INR 3419 Target
More informationMusic Broadcast BUY. Performance Update. CMP Target Price `293 `475. 3QFY2019 Result Update Media. Stock Info Sector Market Cap (Rs cr) Media
Mar-17 May-17 Jul-17 Sep-17 Nov-17 Jan-18 Mar-18 May-18 Jul-18 Sep-18 Nov-18 Jan-19 3QFY2019 Result Update Media January 31, 2019 Music Broadcast Performance Update Y/E March (` cr) 3QFY19 3QFY18 % yoy
More informationDr. Reddy s Laboratories
2QFY2017 Result Update Pharmaceutical November 7, 2016 Dr. Reddy s Laboratories Performance Highlights Y/E March (` cr) 2QFY2017 1QFY2017 % chg (qoq) 2QFY2016 % chg (yoy) Net sales 3,586 3,235 10.9 3,989
More informationPersistent Systems Ltd.
RESULT UPDATE 26 th April2017 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 India Equity Institutional Research II Result Update - Q4FY17 II 26th April, 2017 2 Investment Mode Off, Return Mode On CMP INR 564 Target
More informationKey estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,
: price: EPS: How does our one year outlook change? We retain our negative stance on the stock. We expect s revenue to de-grow by 9% y-o-y on the back of muted execution (client side and clearance delays)
More informationMahindra & Mahindra Ltd.
Nov-15 Jan-16 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 Jul-17 Oct-17 Jan-18 Apr-18 Jul-18 Oct-18 2QFY2019 Result Update Automobile November 15, 2018 Mahindra & Mahindra Ltd. Performance Update Y/E March (` cr)
More informationSiemens. Railways and T&D driving inflows. Source: Company Data; PL Research
Railways and T&D driving inflows November 23, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs1,055 Target Price Rs1,230
More informationHOLD. Coal India Ltd Coal RETAIL EQUITY RESEARCH. Uncertainty remains. GEOJIT BNP PARIBAS Research
COMPANY UPDATE Dec-15 Jan-16 Feb-16 Mar-16 GEOJIT BNP PARIBAS Research Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 RETAIL EQUITY RESEARCH Coal India Ltd Coal BSE CODE:533278 NSE CODE:
More informationUjjivan Financial Services Ltd.: Q3FY18 Result Update
Edelweiss Investment Research Ujjivan Financial Services Ltd.: Q3FY18 Result Update Good show; Robust outlook Ujjivan Financial Services Ltd. (UFS) reported a mixed set of numbers in its Q3FY18 financial
More informationEicher Motors. Continues to ride high! Accumulate. Source: Company Data; PL Research
Continues to ride high! Accumulate November 14, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs30,083 Target
More information